PeerView Oncology

 

Lung
17:03

PeerView Oncology

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung Adenocarcinoma: Should We Initiate IO + Chemo? How Should We Adapt the Treatment if the Tumor Is EGFR+?

FEATURING Edward Garon, John Heymach
  • 248 views
  • November 11, 2020
  • 3
15:20

PeerView Oncology

Locally Advanced and Early NSCLC IO Update: Will IO Change the Multimodal Management of Curative Intent Settings? What Are the Implications for the Multidisciplinary Team?

FEATURING Brendon Stiles
  • 123 views
  • November 11, 2020
  • 1
15:18

PeerView Oncology

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in Clinical Benefit Between 1st Generation EGFR TKIs vs. Osimertinib?

FEATURING Sandip Patel
  • 388 views
  • May 15, 2020
  • 2
02:22

PeerView Oncology

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or Combination Therapy & What Is the Next Step in Case of Liver Mets?

FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
  • 18 views
  • May 28, 2020
05:24

PeerView Oncology

64 y/o Female With Newly Diagnosed Stage 4 NSCLC, EGFR exon 19 Mutation and Symptomatic Brain Lesions: How Would the Management Change?

FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
  • 22 views
  • May 28, 2020
17:21

PeerView Oncology

Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases - The Role of EGFR TKIs: Q & A from the Audience

FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
  • 15 views
  • May 28, 2020
04:37

PeerView Oncology

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Mets: Which EGFR TKIs to Consider and How to Combine Them?

FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
  • 114 views
  • May 28, 2020
  • 1